MAM
Media Maniac’s launched charity drive for underprivileged kids
Mumbai: Volunteering your time to assist a cause you care about is something you will never regret. It will improve your life, acquaint you with your neighbourhood, and link you to people and ideas that will favourably affect your viewpoint for the rest of your life. Helping your community allows you to grow as a person and better understand how you fit into the world around you.
Media Maniacs Group organised a new year charity drive to help underprivileged kids with food, clothes, and stationary in association with the Dulari Devi Foundation. The drive aimed to aid the well-being of the children and provide essential support to those in need. The drive provided the children with food, clothing, and an opportunity to enjoy fun activities. The Media Maniacs group doubled the amount of total donation generated for the charity drive.
Dulari Devi Foundation strives to become the vital link and reach out to those who need help and uplift them as a whole. The foundation aims to uplift education and contribute towards women welfare. The foundation believes the change in society begins with individual effort, and if your cause is good people will automatically connect. The foundation has been actively working for the upliftment of women and children for many years. They believe every child has the right to education and every woman has the right to her individuality. Their purpose encompasses the development of the lifestyle of women and children of all sections and tirelessly strive to achieve that.
Founder Dulari Devi Foundation – political analyst, national media panellist & motivational speaker Preeti Pandey said, “We are delighted with the generosity of Media Maniacs Group in supporting such a noble cause. The drive has helped us to support our children better and fulfil vital requirements. We believe with determination and hard work nothing is impossible,” said
Media Maniacs co-founder Surabhi Trivedi said, “This drive aimed to bring joy in the lives of orphaned children during festive season. Our effort was to provide care and bring a sense of togetherness in these children’s lives. While we may not be able to provide financial assistance, we can make a significant impact in their lives by organizing a charity drive. It’s our duty to help those in need, and this event is an excellent way to do so.”
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
